Ask AI
ProCE Banner Activity

HER2-Directed Therapies for HER2-Positive Advanced BTC and GEA for Patients and Their Caregivers

PDF

This brief downloadable resource features an overview of HER2-positive BTC and GEA, available treatment options for patients with HER2-positive disease, and important clinical considerations for patients with HER2-positive BTC and GEA and their caregivers.

Released: February 27, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients, Inc.

ProCE Banner

Supporters

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Partners

Smart Patients, Inc.

ProCE Banner

Target Audience

This activity is designed to address the educational needs of oncologists, advanced practice providers, pharmacists, nurses, and other HCPs involved in caring for patients with GEA or BTC. Additionally, it aims to empower patients with vital information to actively participate in their treatment decisions, fostering a collaborative approach to their care.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate recent practice-changing data from clinical trials of HER2-targeted agents into treatment plans for HER2+ GEA and BTC to improve patient outcomes

  • Develop individualized treatment strategies for HER2+ GEA and BTC based on current and emerging evidence supporting the use of HER2-targeted therapies in this setting

  • Communicate emerging data and ongoing clinical trial opportunities in HER2+ GEA and BTC to educate colleagues and counsel patients, fostering a collaborative environment for decision-making in their treatment journey

  • Identify patients with HER2+ GEA and BTC who could benefit from HER2-targeted therapy

Disclosure

Primary Author

Amit Mahipal, MD, MPH: consultant/advisor/speaker: Astellas, AstraZeneca, Jazz.